COVID-19 cases are expected to surge again in the U.S., according to data from the Centers for Disease Control And Prevention. This could potentially impact the bottom lines of biopharma companies like Moderna, Inc. (NASDAQ:MRNA), which is expected to report a loss of $4.03 per share in its second-quarter report. However, with experts predicting that COVID-19 will be a recurring theme, these companies may continue to see some revenue from the ongoing pandemic.